Stay updated on Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial

Sign up to get notified when there's something new on the Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    A site-wide notice announces an NIH terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T23:11:17.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T23:36:23.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-10T23:27:27.000Z thumbnail image
  4. Check
    35 days ago
    Change Detected
    Summary
    The study record now displays a 403 Forbidden error instead of the previous content, and a basic header/footer are shown, effectively blocking access to the trial information.
    Difference
    23%
    Check dated 2026-09-19T22:26:27.000Z thumbnail image
  5. Check
    56 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.5 to v3.6.6, indicating a newer build of the page. This change reflects a backend or rendering revision without altering the study text or layout.
    Difference
    0.0%
    Check dated 2026-08-29T20:03:33.000Z thumbnail image
  6. Check
    77 days ago
    Change Detected
    Summary
    Revision: v3.6.5 has been added to the page, replacing Revision: v3.6.4. This indicates a small platform update rather than a change to the study details or page content.
    Difference
    0.0%
    Check dated 2026-08-08T19:42:51.000Z thumbnail image

Stay in the know with updates to Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab+Radiation±Ipilimumab in NSCLC Brain Metastases Clinical Trial page.